Evaluation of two modified ECF regimens in the treatment of advanced gallbladder cancer
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Gallbladder cancer is a rare disease and it is associated with a poor clinical outcome and survival. A standard therapy for it has not been established yet. The aim of this study is to evaluate efficacy and safety of two modified ECF regimens in advanced gallbladder cancer patients. Clinical data of 38 patients with advanced gallbladder cancer treated with modified ECF regimen were reviewed retrospectively. Of them, 21 patients received an epirubicin, cisplatin, and 5-FU/LV combination therapy. Seventeen patients received a chemotherapy of epirubicin, cisplatin, and capecitabine. Partial response was achieved in fourteen (36.84%) patients with a median duration of 5 months (range, 3–13 months), while stable disease was achieved in eight patients (21.05%). The median time to progression was 4.0 months (95% CI, 3.62–4.58 months). And the median overall survival was 9.8 months (95% CI, 7.26–12.34 months). Responders demonstrated better survival than non-responders (median survival time: 16 vs. 6.9 months, P = 0.008). The median survival time for epirubicin-, cisplatin- and capecitabine-treated patients was 9.2 versus 8.9 months for epirubicin-, cisplatin- and 5-FU/LV-treated patients. There was no statistical difference between both treatment groups in terms of survival time (P = 0.769). Regimen-related toxicity resulted in at least one treatment delay or dosage reduction in 63.2 and 34.2% patients, respectively. There were no chemotherapy-related deaths during the study. Modified ECF regimen with epirubicin, cisplatin and 5-FU/LV or substituting capecitabine for 5-FU/LV is still a potentially effective therapeutic chemotherapy for patients with advanced gallbladder cancer, and toxicity was manageable. There was no remarkable difference in efficacy between the two regimens.
- Misra S, Chaturvedi A, Misra NC. Gallbladder cancer. Curr Treat Options Gastroenterol. 2006;9:95–106. CrossRef
- Saika K, Matsuda T. Comparison of time trends in gallbladder cancer incidence (1973–1997) in East Asia, Europe and the USA, from cancer incidence in five continents vols IV-VIII. Jpn J Clin Oncol. 2007;37:974–6. CrossRef
- Lazcano-Ponce EC, Miquel JF, Muñoz N, et al. Epidemiology and molecular pathology of gallbladder cancer. CA Cancer J Clin. 2001;51:349–64. CrossRef
- Glimelius B, Hoffman K, Sjödén PO, et al. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol. 1996;7:593–600.
- Hejna M, Zielinski CC. Nonsurgical management of gallbladder cancer: cytotoxic treatment and radiotherapy. Expert Rev Anticancer Ther. 2001;1:291–300. CrossRef
- Todoroki T. Chemotherapy for gallbladder carcinoma—a surgeon’s perspective. Hepatogastroenterology. 2000;47:948–55.
- Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362:1273–81. CrossRef
- Ross P, Nicolson M, Cunningham D, et al. Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol. 2002;20:1996–2004. CrossRef
- Ellis PA, Norman A, Hill A, et al. Epirubicin, cisplatin and infusional 5-Fluorouracil(5-FU) (ECF) in hepatobiliary tumors. Eur J Cancer. 1995;31A:1594–8. CrossRef
- Morizane C, Okada S, Okusaka T, et al. Phase II study of cisplatin, epirubicin, and continuous-infusion 5-fluorouracil for advanced biliary tract cancer. Oncology. 2003;64:475–6. CrossRef
- Chatni SS, Sainani RS, Mehta SA, et al. Infusion chemotherapy with cisplatinum and fluorouracil in the treatment of locally advanced and metastatic gallbladder cancer. J Cancer Res Ther. 2008;4:151–5. CrossRef
- Park KH, Choi IK, Kim SJ, et al. The efficacy of epirubicin, cisplatin, uracil/tegafur, and leucovorin in patients with advanced biliary tract carcinoma. Cancer. 2005;103:2338–43. CrossRef
- Park SH, Park YH, Lee JN, et al. Phase II study of epirubicin, cisplatin, and capecitabine for advanced biliary tract adenocarcinoma. Cancer. 2006;106:361–5. CrossRef
- Kim MJ, Oh DY, Lee SH, et al. Gemcitabine-based versus fluoropyrimidine-based chemotherapy with or without platinum in unresectable biliary tract cancer: a retrospective study. BMC Cancer 2008;8:374.
- Falkson G, MacIntyre JM, Moertel CG. Eastern cooperative oncology group experience with chemotherapy for inoperable gallbladder and bile duct cancer. Cancer. 1984;54:965–9. CrossRef
- Choi CW, Choi IK, Seo JH, et al. Effects of 5-fluorouracil and leucovorin in the treatment of pancreatic-biliary tract adenocarcinomas. Am J Clin Oncol. 2000;23:425–8. CrossRef
- Taïeb J, Mitry E, Boige V, et al. Optimization of 5-fluorouracil(5-FU)/cisplatin combination chemotherapy with a new schedule of leucovorin, 5-FU and cisplatin (LV5FU2-P regimen) in patients with biliary tract carcinoma. Ann Oncol. 2002;13:1192–6. CrossRef
- Borner MM, Schoffski P, de Wit R, et al. Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomized crossover trial in advanced colorectal cancer. Eur J Cancer. 2002;38:349–58. CrossRef
- Evaluation of two modified ECF regimens in the treatment of advanced gallbladder cancer
Volume 28, Issue 1 Supplement, pp 295-300
- Cover Date
- Print ISSN
- Online ISSN
- Springer US
- Additional Links
- Gallbladder cancer
- Industry Sectors
- Author Affiliations
- 1. Department of General Surgery, Xinhua Hospital, Affiliated to Shanghai Jiaotong University School of Medicine, No. 1665, Kongjiang Road, Shanghai, 200092, China